Lantheus Q3 revenues grow, but so does net loss

By staff writers

November 5, 2021 -- Lantheus Holdings reported revenue growth for the company's third quarter of fiscal 2021, but the company's net loss more than doubled.

For the period (end-September 30), the company said its revenue for the quarter was $102.1 million, an increase of 15.3% from the previous year when it posted sales of $88.5 million. The firm's net loss under generally accepted accounting principles (GAAP) was $13.4 million for the quarter, compared with a net loss of $6.4 million in the previous year.

Lantheus said the revenue growth can be attributed to adoption of its Pylarify prostate-specific member antigen (PSMA) PET imaging agent, as well as continued growth of its Definity and TechneLite products. Lantheus will also continue its ongoing Arrow phase II study of 1095, a PSMA-targeted therapeutic.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking